Cargando…
STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer
Oncogenic mutations in KRAS are among the most common in cancer. Classical models suggest that loss of epithelial characteristics and the acquisition of mesenchymal traits are associated with cancer aggressiveness and therapy resistance. However, the mechanistic link between these phenotypes and mut...
Autores principales: | D’Amico, Stephen, Kirillov, Varvara, Petrenko, Oleksi, Reich, Nancy C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508731/ https://www.ncbi.nlm.nih.gov/pubmed/37732258 http://dx.doi.org/10.1101/2023.09.01.555946 |
Ejemplares similares
-
STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis
por: D'Amico, Stephen, et al.
Publicado: (2018) -
KRAS drives immune evasion in a genetic model of pancreatic cancer
por: Ischenko, Irene, et al.
Publicado: (2021) -
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
por: Ischenko, Irene, et al.
Publicado: (2015) -
IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3
por: Petrenko, Oleksi, et al.
Publicado: (2021) -
KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents
por: Ischenko, Irene, et al.
Publicado: (2017)